Opendata, web and dolomites

PermeAbility SIGNED

PermeAbility - A non-invasive, side-effect-free diagnostic kit for intestinal disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PermeAbility project word cloud

Explore the words cloud of the PermeAbility project. It provides you a very rough idea of what is the project "PermeAbility" about.

blood    reported    clear    stool    clinical    colonoscopy    compromises    bowel    gut    inflammatory    revealing    toxic    rheumatoid    bleedings    35    decision    symptoms    health    small    bacteria    leaky    food    diagnostic    people    intestinal    treatment    select    maintaining    markers    diagnosed    burden    patients    billion    invasive    causing    intestine    mri    ulcers    heavy    economic    performed    disease    restricted    limited    wall    quality    threats    particles    tightly    description    dramatic    causes    syndrome    solely    normally    direct    plasma    ibd    diabetes    life    stream    risk    facts    connected    cells    articles    form    evaluation    waste    indirect    worldwide    poses    leak    surgeries    structure    obesity    though    pain    arthritis    informed    removal    reinforced    urges    lgs    lesions    inflammation    diagnosis    acute    unnecessary    besides    compromise    microcapsule    lifetag    diarrhea    assessing    qualitative    permeability    abdominal    disposing    digestion    biopsy    extensive    proprietary    organization    damage    rupture    barrier   

Project "PermeAbility" data sheet

The following table provides information about the project.

Coordinator
LIEFTAG LDA 

Organization address
address: BIOCANT - ASSOCIACAO DE TRANSFERENCIA DE TECNOLOGI
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website https://lifetag.pt
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIEFTAG LDA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

'Inflammatory Bowel Disease (IBD) is a form of acute inflammation to the small intestine that causes ulcers and extensive damage of the gut barrier causing it to rupture. This causes bleedings, abdominal pain, diarrhea, and a dramatic reduction of the quality of life. The intestinal barrier is normally a very well organised structure in which the cells are tightly connected maintaining the barrier. Moreover, IBD lesions compromise this intestinal organization and increases intestinal permeability, which is called leaky gut syndrome (LGS) being also a pre-disposing factor for several other health problems. LGS compromises digestion of food particles and removal of toxic waste products, and allows bacteria to 'leak' through the intestine to the blood stream. Besides in IBD, LGS is also common in people with health conditions such as obesity, rheumatoid arthritis and type 2 diabetes. Even though IBD poses significant threats to a patients’ health and a heavy direct and indirect economic burden, diagnosis of this condition is still limited assessing indirect parameters like general inflammation markers in plasma and stool and evaluation based by comparison on the patients symptoms description. The direct measures are also performed but are restricted to very invasive methods like biopsy or solely qualitative like MRI and microcapsule colonoscopy. In this way it is reported in several clinical articles a clear need for new diagnostic methods in IBD reinforced by facts like 35% of the performed surgeries for treatment revealing unnecessary and 1.9 billion people worldwide at risk for early lesions and IBD development not being diagnosed. In this way clinical practice urges for new methods for the assessment of lesions in the intestinal wall. Lifetag’s has developed PermeAbility, a new proprietary test to measure intestinal permeability to better select patients at high risk of IBD , leading to better informed clinical decision making, diagnosis, and treatment.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERMEABILITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERMEABILITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Didimo (2019)

Humanity in Digital Communication

Read More